Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
VERU · NASDAQ · Pharmaceutical Preparations
Veru (VERU) · oqro.io/stocks/VERU · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.09−0.03 (−1.42%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Veru (VERU) filed 1 open-market purchase in the last 90 days; the latest was filed on Aug 17, 2026.
Since 2000, Veru insiders reported 127 open-market purchases and 187 sales on Forms 4 and 5, with purchases in 17 different years, most recently 2026.
No open-market sale by an insider of Veru (VERU) was filed with the SEC in the last 90 days.
No trade in Veru (VERU) was disclosed by a member of Congress in the last 12 months.
Veru's next results are expected on Dec 15, 2026, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−16.7% (−$0.42) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $2.51 on Nov 13, 2025 to $2.09 on Nov 13, 2026 (−16.7%). Disclosed in this range: 1 insider trade, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Miami, Fl.
Last 12 months
−16.7%
Market value
$35.6M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.5M shares sold short (8.8% of shares outstanding), +2.3% vs the previous count, 13.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Year earlier: $0
Free cash flow, last 12 months
−$26M
This quarter −$5.47M, a year earlier −$5.48M
Net debt
—
Debt —, cash $23.9M, at Jun 30, 2026
Net income, last 12 months
−$13.6M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 10, 2026.
Insider buying
First insider buy since Feb 2025Traded Aug 13 · filed 4 days later
Since the trade −22.6% · S&P 500 −3.0% · to Nov 13
Traded Feb 18 – Feb 19, 2025 · largest single transaction ~$52K
Feb 18, 2025~$52K · 95K sh @ $0.5503
DetailsOfficial recordFeb 19, 2025~$32K · 55K sh @ $0.5833
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Veru reported 127 open-market purchases and 187 sales since 2000; purchases in 17 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $4.8K1×1 trade | — |
| 2025 | $84K2×2 trades | — |
| 2024 | $22K3×3 trades | $335K6×6 trades |
| 2022 | — | $2M1×1 trade |
| 2021 | $82K2×2 trades | $1.25M2×2 trades |
| 2020 | $57K5×5 trades | $3.49M2×2 trades |
| 2019 | $185K17×17 trades | $597K31×31 trades |
| 2018 | $474K21×21 trades | — |
| 2017 | $584K32×32 trades | — |
| 2016 | $99K15×15 trades | — |
| 2015 | $92K6×6 trades | — |
| 2014 | $82K6×6 trades | $1.23M1×1 trade |
| 2013 | $88K5×5 trades | $1.4M6×6 trades |
| 2012 | — | $6.08M64×64 trades |
| 2011 | — | $606K7×7 trades |
| 2010 | $119K7×7 trades | $3.15M31×31 trades |
| 2009 | — | $1.92M15×15 trades |
| 2008 | $6.3K1×1 trade | $319K9×9 trades |
| 2007 | — | $743K6×6 trades |
| 2006 | $78K2×2 trades | $69K6×6 trades |
| 2002 | $3.5K1×1 trade | — |
| 2000 | $1.7K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in obesity & overweight. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last results
Aug 10, 2026
More than 30 days ago
Next results, expected
Dec 15, 2026
after the market closes; the date can move until the company confirms it
Purchases after results
84%
103 of 123 insider purchases since 2007 came within 30 days after a results announcement
From Veru's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Veru's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
On the public record for Veru over the 12 months to Nov 15, 2026: 1 clinical trial.